Clinical and Experimental Reproductive Medicine

  • 제43권1호
  • /
  • Pages.26-30
  • /
  • 2016
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples

  • Song, Seung-Hun (Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Kim, Dong Suk (Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University) ;
  • Shim, Sung Han (Department of Genetics, CHA University) ;
  • Lim, Jung Jin (Chronic Disease Program, Ottawa Hospital Research Institute) ;
  • Yang, Seung Choul (Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University)
  • 투고 : 2015.10.30
  • 심사 : 2016.01.15
  • 발행 : 2016.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: We aimed to investigate the prevalence of erectile dysfunction (ED) and the usage of phosphodiesterase type 5 (PDE5) inhibitors for ED treatment in infertile couples. Methods: A total of 260 male partners in couples reporting infertility lasting at least 1 year were included in this study. In addition to an evaluation of infertility, all participants completed the International Index of Erectile Function (IIEF)-5 questionnaire to evaluate their sexual function. The participants were asked about their use of PDE5 inhibitors while trying to conceive during their partner's ovulatory period and about their concerns regarding the risks of PDE5 inhibitor use to any eventual pregnancy and/or the fetus. Results: Based on the IIEF-5 questionnaire, 41.5% of the participants (108/260) were classified as having mild ED (an IIEF-5 score of 17-21), while 10.4% of the participants (27/260) had greater than mild ED (an IIEF-5 score of 16 or less). The majority (74.2%, 193/260) of male partners of infertile couples had a negative perception of the safety of using a PDE5 inhibitor while trying to conceive. Only 11.1% of men (15/135) with ED in infertile couples had used a PDE5 inhibitor when attempting conception. Conclusion: ED was found to be common in the male partners of infertile couples, but the use of PDE5 inhibitors among these men was found to be very low. The majority of male partners were concerned about the risks of using PDE5 inhibitors when attempting to conceive. Appropriate counseling about this topic and treatment when necessary would likely be beneficial to infertile couples in which the male partner has ED.

키워드

참고문헌

  1. Kessler LM, Craig BM, Plosker SM, Reed DR, Quinn GP. Infertility evaluation and treatment among women in the United States. Fertil Steril 2013;100:1025-32. https://doi.org/10.1016/j.fertnstert.2013.05.040
  2. Shindel AW, Nelson CJ, Naughton CK, Ohebshalom M, Mulhall JP. Sexual function and quality of life in the male partner of infertile couples: prevalence and correlates of dysfunction. J Urol 2008;179:1056-9. https://doi.org/10.1016/j.juro.2007.10.069
  3. Ramezanzadeh F, Aghssa MM, Jafarabadi M, Zayeri F. Alterations of sexual desire and satisfaction in male partners of infertile couples. Fertil Steril 2006;85:139-43. https://doi.org/10.1016/j.fertnstert.2005.07.1285
  4. O'Brien JH, Lazarou S, Deane L, Jarvi K, Zini A. Erectile dysfunction and andropause symptoms in infertile men. J Urol 2005;174:1932-4. https://doi.org/10.1097/01.ju.0000177453.14334.a2
  5. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257-61. https://doi.org/10.1046/j.1464-410X.1996.10220.x
  6. Kalsi JS, Bahadur G, Muneer A, Ozturk O, Christopher N, Ralph DJ, et al. Novel PDE5 inhibitors for the treatment of male erectile dysfunction. Reprod Biomed Online 2003;7:456-61. https://doi.org/10.1016/S1472-6483(10)61890-1
  7. Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, et al. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health 2014;32:18-27. https://doi.org/10.5534/wjmh.2014.32.1.18
  8. Bechara A, Casabe A, De Bonis W, Helien A, Bertolino MV. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med 2010;7:3736-42. https://doi.org/10.1111/j.1743-6109.2010.01965.x
  9. World Health Organization. WHO laboratory manual for the examination and processing of human semen. 5th ed. Geneva: World Health Organization; 2010.
  10. Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002;14:245-50. https://doi.org/10.1038/sj.ijir.3900859
  11. Peters RJ Jr, Johnson RJ, Kelder S, Meshack AF, Jefferson T. Beliefs and social norms about sildenafil citrate (Viagra) misuse and perceived consequences among Houstonian teenage males. Am J Mens Health 2007;1:208-12. https://doi.org/10.1177/1557988307303299
  12. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc (2003) 2005;45:63-72. https://doi.org/10.1331/1544345052843165
  13. Fisch JD, Behr B, Conti M. Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors. Hum Reprod 1998;13:1248-54. https://doi.org/10.1093/humrep/13.5.1248
  14. Cuadra DL, Chan PJ, Patton WC, Stewart SC, King A. Type 5 phosphodiesterase regulation of human sperm motility. Am J Obstet Gynecol 2000;182:1013-5. https://doi.org/10.1067/mob.2000.105435
  15. Lefievre L, De Lamirande E, Gagnon C. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction. J Androl 2000;21:929-37.
  16. Fabbri A, Aversa A, Isidori A. Sildenafil and erectile dysfunction. J Endocrinol Invest 1999;22:486-92. https://doi.org/10.1007/BF03343595
  17. Glenn DR, McVicar CM, McClure N, Lewis SE. Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro. Fertil Steril 2007;87:1064-70. https://doi.org/10.1016/j.fertnstert.2006.11.017
  18. du Plessis SS, de Jongh PS, Franken DR. Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril 2004;81:1026-33. https://doi.org/10.1016/j.fertnstert.2003.09.054
  19. Mostafa T. Oral phosphodiesterase-5 inhibitors and sperm functions. Int J Impot Res 2008;20:530-6. https://doi.org/10.1038/ijir.2008.29
  20. Tur-Kaspa I, Segal S, Moffa F, Massobrio M, Meltzer S. Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies. Hum Reprod 1999;14:1783-4. https://doi.org/10.1093/humrep/14.7.1783

피인용 문헌

  1. Evaluation of the effects of chronic stress applied from the prepubertal to the adult stages or only during adulthood on penile morphology in rats vol.22, pp.2, 2016, https://doi.org/10.1080/10253890.2018.1553946
  2. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: A National Cross‐sectional Survey vol.51, pp.9, 2016, https://doi.org/10.1111/and.13364